Excision Bio licenses CRISPR technology from UC Berkeley

Excision BioTherapeutics has become the first company to secure exclusive licences from the University of California (UC), Berkeley for “newly discovered” CRISPR gene editors.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

UC, Berkeley files brief in CRISPR Federal Circuit case

31 July 2017 The University of California, Berkeley has filed a brief at the US Court of Appeals for the Federal Circuit in its appeal against a patent decision on the CRISPR/Cas9 technology.

Americas

EPO to grant UC, Berkeley CRISPR patent

28 March 2017 The European Patent Office has revealed its intention to grant a patent covering the CRISPR gene-editing technology to the University of California, Berkeley, the University of Vienna, and inventor Emmanuelle Charpentier.

More on this story

Americas

UC, Berkeley files brief in CRISPR Federal Circuit case

31 July 2017 The University of California, Berkeley has filed a brief at the US Court of Appeals for the Federal Circuit in its appeal against a patent decision on the CRISPR/Cas9 technology.

Americas

EPO to grant UC, Berkeley CRISPR patent

More on this story

Americas

UC, Berkeley files brief in CRISPR Federal Circuit case

31 July 2017 The University of California, Berkeley has filed a brief at the US Court of Appeals for the Federal Circuit in its appeal against a patent decision on the CRISPR/Cas9 technology.

Americas

EPO to grant UC, Berkeley CRISPR patent